The safety-first AI company is trying to become a drug company. That's a much harder pivot than it sounds.
On Tuesday, Anthropic launched Claude Science, a version of Claude wired into the tools scientists actually use, including Benchling, PubMed, 10x Genomics, and BioRender. The bigger news came in the same announcement: Anthropic is now running its own internal drug discovery programs, targeting the kinds of diseases Big Pharma has largely written off as unprofitable, according to Anthropic.
Eric Kauderer-Abrams, who runs Anthropic's life sciences work, told STAT the goal is to change life sciences the way Claude Code changed programming. He also said Anthropic wants to "live it" alongside the researchers it's selling to. In plain terms, the company is putting its own models to work on actual drug candidates instead of licensing the tech and walking away.
The quieter signal came a few months earlier. Anthropic paid around $400 million to acquire Coefficient Bio, a team that had already been building agent systems for biology. You don't spend that on a subsidiary to run a research preview.
Anthropic is not alone here. Isomorphic Labs, spun out of DeepMind, has been running drug design programs with Novartis and Eli Lilly, and Fiona Marshall, who leads biomedical research at Novartis, has said the collaboration has opened up chemistry that traditional methods couldn't reach. John Jumper, the Nobel-winning AlphaFold researcher, quietly joined Anthropic from DeepMind earlier this summer. The talent is moving.
The problem is what everyone in the field keeps running into. A recent Latent Labs paper put it plainly: the rate-limiting step in early drug discovery isn't designing molecules anymore, it's testing them in a lab. One round of experiments runs anywhere from $80,000 to over $1 million, and no AI-generated therapeutic has actually reached the market yet. Designing the drug on a computer is the easy part. Proving it works in a body is where the years and the money live.
That's the wall Anthropic is walking into. Its customer list already includes Sanofi, Genmab, and Novo Nordisk, which said Claude has become the standard for how it automates content in drug development. Real revenue, real usage, mostly document work. Turning that into an approved drug is a completely different game, and it's a game that has humbled every AI-first drug company that's tried it.
Even Vas Narasimhan, the CEO of Novartis, told a Harvard audience last September that he had a "somewhat muted view" of AI's impact on drug discovery and didn't feel the technology was close to meaningfully changing how new medicines get found. That's the CEO of one of Anthropic's biggest customers being polite in public.
Anthropic has done the thing every AI company eventually has to do, which is pick a hard problem in the physical world and try to solve it. Drug discovery is a strange choice, because it's the one field where the last decade of AI hype has produced the fewest actual products. Every AI drug company you've heard of has raised enormous rounds, promised revolutions, and delivered mostly slide decks. What makes Anthropic worth watching is that it's not selling to pharma from the outside, it's trying to become pharma from the inside, with the model quality and the capital to actually take the swing. Whether that ends in a real drug or another expensive lesson about how biology doesn't care how smart your chatbot is, we'll find out in about a decade.
